kabutan

Meiji Holdings Co., Ltd.(2269) Summary

2269
TSE Prime
Meiji Holdings Co., Ltd.
3,618.0
JPY
-17.0
(-0.47%)
Jan 29, 3:30 pm JST
23.65
USD
Jan 29, 1:30 am EST
Result
PTS
outside of trading hours
3,609.9
Jan 29, 3:25 pm JST
Summary Chart Historical News Financial Result
PER
18.1
PBR
1.31
Yield
2.90%
Margin Trading Ratio
5.26
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
3,600.0 JPY 23.51 USD
Previous Close Jan 28
3,635.0 JPY 23.81 USD
High Jan 29, 9:00 am
3,628.0 JPY 23.69 USD
Low Jan 29, 9:05 am
3,578.0 JPY 23.37 USD
Volume
1,030,000
Trading Value
3.72B JPY 0.02B USD
VWAP
3610.22 JPY 23.6 USD
Minimum Trading Value
361,800 JPY 2,365 USD
Market Cap
1.02T JPY 6.72B USD
Number of Trades
2,882
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
High
1-Year Average
2,822
1-Year High Feb 10, 2025
20,343
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 79,600 321,200 4.04
Jan 16, 2026 77,200 214,400 2.78
Jan 9, 2026 78,300 222,100 2.84
Dec 26, 2025 79,700 227,200 2.85
Dec 19, 2025 94,600 242,600 2.56
Company Profile
Meiji Holdings Co., Ltd. was formed through the integration of Meiji Seika and Meiji Dairies. It is the largest company in the confectionery and dairy industries. The company's pharmaceutical business is experiencing rapid growth, and it is expanding globally.
Sector
Foods
Meiji Holdings Co., Ltd. operates in two business segments: Food and Pharmaceuticals. In the Food segment, the company handles a wide range of products including dairy products, confectioneries, nutritional foods, and animal feed, conducting business through numerous subsidiaries and affiliated companies both domestically and internationally. The Pharmaceutical segment focuses primarily on prescription drugs and veterinary medicines, manufacturing and selling these products through domestic and overseas subsidiaries. As a pure holding company, Meiji Holdings is responsible for formulating group-wide strategies and managing operations. Meiji Co., Ltd. is positioned as the core company in the food business, while Meiji Seika Pharma Co., Ltd. and KM Biologics Co., Ltd. are the core companies in the pharmaceutical business. The company is also focusing on global expansion, with numerous overseas subsidiaries, particularly in Asia.